1stOncology™: Cancer Intelligence Service – Page 14239 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Knight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan & License Agreement

On February 20, 2019 Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative pharmaceutical products, reported it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics Inc. ("Triumvira") (Press release, Knight Therapeutics, FEB 20, 2019, View Source [SID1234533509]). The US$5 million secured loan has a term of 1 year and will enable Triumvira to accelerate activities to bring its innovative lead program into the clinic. In addition, Triumvira shall grant Knight an exclusive license to commercialize Triumvira’s future approved products for Canada, Israel, Mexico, Colombia and for TAC01-CD19 for Israel, Mexico, Brazil and Colombia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"We are excited to help Triumvira accelerate development of their novel platform for engineering T cells to attack cancer," said Jonathan Ross Goodman, Chief Executive Officer of Knight.

"We are thrilled both with this Knight solution to our short-term funding need and in having Knight as our proven successful Canadian, Israeli and South American distribution partner," said Dr. Paul Lammers, President and Chief Executive Officer.

Peloton Therapeutics Secures $150 Million in Series E Financing

On February 20, 2019 Peloton Therapeutics, Inc., a drug discovery and development company advancing first-in-class oral medicines for cancer and other serious conditions, reported the closing of an oversubscribed $150 million Series E financing (Press release, Peloton Therapeutics, FEB 20, 2019, View Source [SID1234533508]). The financing was led by RA Capital Management and was joined by new investors including Eventide Asset Management, Biotechnology Value Fund, OrbiMed, EcoR1 Capital, Vida Ventures, Curative Ventures and Driehaus Capital Management LLC. Peloton’s existing investors, including The Column Group, Nextech Invest Ltd, Topspin Fund LP, Tichenor Ventures LLC and Foresite Capital Management also participated in the financing.

"We are delighted to have received such avid support from this eminent group of healthcare investors," said John Josey, Ph.D., Peloton’s Chief Executive Officer. "Proceeds from this financing will be used to advance Peloton’s research and development pipeline, including our lead drug candidate, PT2977, a potent and selective oral HIF-2α inhibitor."

"RA Capital is excited to support Peloton as it moves towards a Phase 3 trial of PT2977 for patients with metastatic renal cell carcinoma and pushes forward clinical development of this drug candidate in Von Hippel-Lindau disease, a familial cancer syndrome for which there are currently no approved drugs," said Derek DiRocco, Ph.D., Principal, RA Capital Management.

AVEO Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference

On February 20, 2019 AVEO Oncology (NASDAQ:AVEO) reported that Michael Bailey, president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.m. Eastern Time (Press release, AVEO, FEB 20, 2019, View Source [SID1234533507]).

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference

On February 20, 2019 -Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy company, reported that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City (Press release, Rocket Pharmaceuticals, FEB 20, 2019, View Source [SID1234533506]). The fireside chat will take place on Wednesday, February 27, 2019, at 11:00 a.m. Eastern Time.

A live audio webcast of the fireside chat will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

PharmaMar’s Zepsyre® ATLANTIS trial in small-cell lung cancer will be an oral presentation at the IASLC’s Targeted Therapies annual meeting

On February 20, 2019 PharmaMar’s (MSE:PHM) clinical trial of Zepsyre (lurbinectedin) in combination with doxorubicin in relapsed small-cell lung cancer patients reported that it will be presented at an oral session at the 19 th annual meeting on Targeted Therapies in Lung Cancer that is organized by the International Association for the Study of Lung Cancer (IASLC), taking place in in Santa Monica, California, from the 20th to the 23rd of February 2019 (Press release, PharmaMar, FEB 20, 2019, View Source [SID1234533501]). This specialized meeting is designed to provide information about ongoing clinical trials of the newest and most promising therapies for lung cancer.

The presentation will be on Thursday February 21st, at 10:25 Pacific time, by Dr. William J. Petty, Director, Thoracic Oncology Program, Professor of Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine.

Zepsyre (lurbinectedin) is currently awaiting results after final analysis during 2019, from two trials that both completed recruitment in 2018. The multi-center basket trial cohort in relapsed small-cell lung cancer that recruited 105 patients to be treated with Zepsyre monotherapy and it is hoped that results are presented at a future congress on oncology.

In addition, the randomized multi-center ATLANTIS phase III clinical trial that enrolled 613 patients with relapsed small cell lung cancer to be treated with either Zepsyre in combination with doxorubicin versus Topotecan or CAV, is due to report top line results around year end 2019.